

Review Article

Non-Helicobacter pylori, non-NSAID peptic ulcer disease

ABSTRACT

Peptic ulcers are common although the pattern of aetiology is changing. The traditionally most frequent causes of *Helicobacter pylori* infection and non-steroidal anti-inflammatory toxicity are likely to assume less relative importance as the proportion of cases attributed to other causes rises. Primary care physicians should be aware the pathogenesis of peptic ulceration in non-*H.pylori* non-NSAID induced disease. This article considers the various less prevalent causes of peptic ulcers and outlines their evaluation and management. Greater awareness of such conditions will improve patient care when traditional causes and remedies are absent.

KEYWORDS

peptic ulcer; non-*H.pylori*; non-NSAID


ABBREVIATIONS

PUD: peptic ulcer disease; **NSAID:** non-steroidal anti-inflammatory drug; **PPI:** proton pump inhibitor; ***H.pylori:*** *Helicobacter pylori*

1. INTRODUCTION

Peptic ulcer disease (PUD) embodies both gastric and duodenal ulcers. Ulcers are defined as breaks in the mucosal surface of 5mm or more which penetrate into the

20 submucosa (Figure 1). Mucosal damage smaller than 5mm in size or which involves
 21 mucosal disruption but does not breach the submucosa is known as an erosion
 22 (Figure 2) [1,2]. Peptic ulceration occurs as a consequence of an imbalance between
 23 protective and destructive influences acting on the gastroduodenal mucosa [3].



29 PUD is a common condition with a worldwide prevalence of approximately 1.5% [4].
 30 *Helicobacter pylori* (*H.pylori*) infection and the use of non-steroidal anti-inflammatory
 31 medications (NSAIDs) account for the large majority of PUD in developed areas [5].
 32 Although PUD remains common its incidence in the western world is declining,
 33 primarily reflecting the falling proportion of ulcers caused by *H.pylori* or NSAID use
 34 [6]. The drop in rates of *H.pylori* induced disease is probably associated with
 35 improved hygiene and living conditions while the smaller relative contribution of
 36 NSAID toxicity is possibly because of a combination of growing proton pump inhibitor
 37 (PPI) use and the advent of COX-2 selective anti-inflammatory agents [7-10].

38 Approximately 12% of cases of PUD are not associated with *H.pylori* or NSAID
 39 ingestion [11,12]. It is therefore important that general practitioners are able to
 40 identify alternative explanations for peptic ulceration when patients test negative for
 41 *H.pylori* or deny NSAID ingestion and have at least some knowledge on how to
 42 approach such cases.

43 2. INITIAL APPROACH TO SUSPECTED PEPTIC ULCERS

44 Patients with peptic ulceration commonly complain of upper abdominal pain or
45 discomfort which varies with meals. The pain of gastric ulcers is classically worsened
46 by meals while duodenal ulcer pain is classically relieved by eating and worsened
47 during the night. PUD is also an important cause of hematemesis and must be
48 considered in any patient with that presentation. Physical examination may reveal
49 epigastric tenderness but is regularly unremarkable.

50 The differential diagnosis for a patient with dyspeptic symptoms is wide. Common
51 problems include PUD, gastro-oesophageal reflux, malignancy, infectious gastritis or
52 functional dyspepsia. In addition, there is a host of non-gastrointestinal pathologies
53 which may mimic the symptomatology of PUD.

54 Individuals with ulcer pain do not always require further investigation. If younger than
55 55 years of age and accompanied by no alarm features patients may receive
56 sufficient treatment simply with lifestyle changes and acid suppression. Urgent upper
57 endoscopy is mandated in the presence of alarm features such as anaemia, weight
58 loss, gastrointestinal bleeding or first presentations in patients older than 55 years of
59 age.

60 A definitive cause should be sought for those younger patients who remain
61 symptomatic with dyspepsia after four weeks of antisecretory treatment. Exclusion of
62 *H.pylori* or NSAID overuse is the first step. Non-invasive methods in the workup of
63 *H.pylori* include stool antigens, serology and the urea breath test, all of which are
64 more than 90% sensitive [13]. Patients with confirmed infection or acknowledgement
65 of NSAID consumption can then be managed accordingly.

66 In patients testing negative for *H.pylori* or denying NSAID intake, the clinician's initial
67 consideration should be that *H.pylori* testing was falsely negative or that the patient's
68 recollection of NSAID consumption is misleading. These aetiologies remain the most
69 significant causes PUD and identifying them can avoid further unnecessary workup
70 or treatment. Concealed NSAID use or false-negative *H.pylori* tests are probably the
71 most common reasons for apparently *H.pylori*-negative, NSAID-negative PUD.
72 Patients should be questioned directly about NSAID intake and should be retested
73 for *H.pylori*, preferably with two or more different modalities given that no one test is
74 completely sensitive. Regarding workup for *H.pylori* it should be recognised that
75 current or recent use of PPIs or antibiotics may render non-invasive tests falsely
76 negative [14,15].

77 Patients who are negative for *H.pylori* with non-invasive methods need referral for
78 upper gastrointestinal endoscopy to either confirm *H.pylori* colonisation formally or
79 establish an alternative diagnosis. The provisional diagnosis of peptic ulcer should
80 also be revisited given that the list of causes of dyspeptic symptoms is broad.

81 **3. EVALUATION OF NON-NSAID NON-H.PYLORI DISEASE**

82 Not all cases of dyspepsia can be explained by peptic ulcers produced by *H.pylori* or
83 NSAID ingestion. There are various atypical causes of PUD and in many cases
84 dyspepsia is not related to PUD at all. Depending on the clinical impression other
85 gastrointestinal or non-gastrointestinal diagnoses might be contemplated or
86 investigated.

87 Patients with suspected *H.pylori*-negative NSAID-negative PUD should receive acid
88 suppression therapy while they await examination with upper endoscopy.
89 Identification of peptic ulceration on endoscopy should prompt the general

90 practitioner to search for a causative agent, with the assistance of a
91 gastroenterologist if necessary. Failure to discover a cause is associated with
92 frequent ulcer recurrence and a significantly higher mortality from ulcer bleeding [16].

93 A careful history and physical examination may identify clues to an underlying
94 diagnosis. At minimum a diagnostic workup should include a serum gastrin level.
95 Further investigations depend on clinical circumstances and what diagnoses appear
96 plausible.

97 **4. OTHER CAUSES OF PEPTIC ULCER DISEASE**

98 **4.1. Infection**

99 Both herpes simplex virus type 1 (HSV-1) and cytomegalovirus (CMV) have been
100 implicated in the aetiopathogenesis of PUD. This is supported by several studies
101 showing a presence of both HSV-1 and CMV antibodies in ulcer biopsy specimens,
102 mostly in immunosuppressed patients, without systemic evidence of infection
103 [17,18]. Although there appears to be a convincing causative relationship the
104 mechanisms of ulcer formation by these pathogens is not established [17].

105 HSV-1 and CMV infections account for a very low number of PUD cases overall.
106 There is no placebo-controlled data to guide treatment and management decisions
107 are largely empirical. Immunocompetent hosts typically recover without the need for
108 intervention, however ulcer healing can be aided with the prescription of an
109 antisecretory agent for four weeks, such as omeprazole 20mg daily or ranitidine
110 300mg daily. In immunosuppressed patients or those with severe disease
111 intravenous antiviral therapy is usually required.

112 **4.2. Medications other than NSAIDs**

There are a number of common drugs other than NSAIDs which may rarely be responsible for gastritis and subsequent ulcerogenesis. Although these relationships exist NSAIDs remain by far the most significant medication class associated with peptic ulceration.

4.2.1. Paracetamol.

In the dose range used by most patients paracetamol does not increase the risk of peptic ulceration. However, consumption in excess of 2 grams per day is associated with moderately elevated risk of upper gastrointestinal haemorrhage and perforation [19,20]. This association appears to be independent of any confounding factors.

4.2.2. Spironolactone.

Spironolactone has been found in several case-control studies to be linked with peptic ulcer formation. The relationship seems to be causative with a relative risk of upper gastrointestinal haemorrhage or peptic ulcer of 2.7 in patients taking spironolactone versus randomly selected controls [21]. Risk of PUD rises proportionally with increasing spironolactone dose. The mechanism of gastroduodenal toxicity is probably related to inhibition of fibrous tissue formation, a process that relies on mineralocorticosteroids [22].

4.2.3. Selective serotonin reuptake inhibitors (SSRIs).

SSRIs are known to cause gastroduodenal ulcers. The intake of SSRIs also exacerbates bleeding in patients with *H.pylori* or NSAID-induced ulcers [23]. In a recent meta-analysis SSRI use raised the likelihood of upper gastrointestinal haemorrhage overall by an odds ratio of 2.36 and by an odds ratio of 6.11 in patients taking concomitant NSAIDs [24]. A proposed mechanism for this trend is that

inhibition of serotonin reuptake impairs platelet aggregation. The highest risk is seen with fluoxetine, paroxetine and sertraline [24].

4.2.4. Bisphosphonates.

Bisphosphonates occasionally cause peptic ulceration, mostly in the stomach. This finding has been observed in several blinded randomised trials [25,26]. Alendronate is the agent most implicated with gastric ulcers demonstrable endoscopically in approximately 10% of patients after just 2 weeks of treatment [26]. Risedronate and pamidronate have also proven ulcerogenic although to a lesser extent [26-28]. Patients in these studies were screened with endoscopy and presence of ulcers was not shown to correlate with symptoms or gastrointestinal haemorrhage so the clinical importance of this finding is uncertain.

4.2.5. Corticosteroids.

The association between glucocorticoid use and PUD is controversial. Although most physicians continue to consider corticosteroids ulcerogenic based on clinical experience, such a relationship has not been established in the literature [29-31]. Most major studies have demonstrated no statistically significant risk of peptic ulcer associated with corticosteroid use alone with elevated risk only appreciable in patients also consuming NSAIDs [30,31]. One meta-analysis did identify an increased risk of gastrointestinal bleeding or perforation with corticosteroid use at an odds ratio of 1.42 in hospitalised patients [32]. Such problems in this setting were more likely a result of comorbidities or medical treatments which may have been potentiated by corticosteroid use, as opposed to direct injury and ulceration by corticosteroids alone.

4.3. Gastrinoma

Gastrin-secreting adenomas, or 'gastrinomas', secrete excessive gastric acid which can produce gastric or duodenal ulcers. This represents the classic entity known as Zollinger-Ellison syndrome. The commonest location of gastrinomas is the duodenum followed by the pancreas. These tumours account for less than 1% of PUD cases and have an overall prevalence of 1-2 patients per million, so are exceptional, but should be considered in patients with a family history of ulcers [13,33]. In general practice the possibility of gastrinoma is usually raised by measuring fasting serum gastrin. Formal diagnosis and treatment is complex and should ideally be overseen by a specialist.

Management of gastrinomas is both medical and surgical. Medical therapy comprises high dose PPIs which are generally effective at controlling symptoms and peptic ulceration. For example, the patient could be commenced on omeprazole 60mg daily for several weeks followed by dose adjustment according to response. Maximum treatment should not exceed 360mg daily in divided oral doses. The PPI should be tapered in the longer term to a minimal level necessary to control gastric acid output. Gastrinomas are malignant and metastatic disease leads to death in many patients. Therefore, in combination with pharmacotherapy patients also require follow up and prompt consideration for surgical resection which may be curative in early disease.

4.4. Carcinoid Syndrome

Carcinoid syndrome is a constellation of symptoms produced by a carcinoid tumour, a neuro-endocrine neoplasm typically found in the gastrointestinal tract. Carcinoid tumours are capable of producing an array of hormones, of which histamine and gastrin most likely bring on peptic ulceration. The secretion of vasoactive substances

184 by carcinoid tumours elicits a diverse range of possible clinical manifestations with
185 classic clues including diarrhoea or cutaneous flushing.

186 The diagnostic test most useful to the general practitioner is measurement of urinary
187 5-hydroxyindoleacetic acid (5-HIAA). 5-HIAA is a breakdown product of serotonin
188 metabolism. Performing this test involves a 24-hour urine collection with subsequent
189 measurement of total 5-HIAA content. It is both highly sensitive and specific for
190 carcinoid syndrome. In most laboratories a normal total 5-HIAA excretion is less than
191 approximately 8mg in 24 hours.

192 The management of carcinoid syndrome as a whole is a complex and specialised
193 area however the ulcer element of this syndrome can be effectively controlled with
194 antacids and histamine H₂ receptor blockers such as ranitidine. An appropriate
195 course of ranitidine would be 300mg once daily, taken in the evenings. Acid
196 suppression can be stepped down empirically according to the individual patient,
197 once systemic control of carcinoid syndrome is achieved. Regarding the disease in
198 general, treatment with somatostatin analogues such as octreotide are usually highly
199 effective in controlling symptoms while surgical resection of the tumour is often
200 necessary for cure.

201 **4.5. Radiotherapy**

202 Irradiation directed at the abdomen or pelvis can result in peptic ulceration. The
203 incidence of radiation ulcers is not insignificant. In a retrospective chart analysis of
204 100 patients receiving radiotherapy for liver tumours, 5% subsequently developed
205 gastroduodenal ulcers within 5 months of treatment. In this series only patients with
206 suggestive symptoms underwent endoscopy to confirm the diagnosis. One of the five
207 patients to develop an ulcer was taking regular NSAIDs [35].

208 Radiation ulcers are usually located in the proximal duodenum. Symptoms begin in
209 the first several months following cessation of radiation therapy [34]. Irradiation
210 therapy for gynaecological tumours or rectal cancer are the most frequently
211 associated treatments. Management of radiation-induced ulceration is challenging as
212 it tends to be unremitting to acid suppression and most cases will require surgery
213 [34,36].

214 **4.6. Sarcoidosis**

215 Sarcoidosis can affect virtually any organ and the gastrointestinal tract is not exempt.
216 Gastrointestinal sarcoidosis is very rare with granulomatous gastritis being the most
217 frequent finding in this setting [37]. Gastritis alone tends to be asymptomatic but
218 erosive gastritis may progress to ulcer at which point most patients present with
219 symptoms. A clue to this diagnosis is that gastroduodenal disease almost exclusively
220 occurs in patients demonstrating pre-existing pulmonary manifestations of
221 sarcoidosis [38].

222 Trial data on the management of gastric or duodenal sarcoidosis is scant. In general,
223 asymptomatic patients probably do not require treatment and may be monitored for
224 development of symptoms. If intervention is indicated, patients should be
225 commenced on PPI therapy and glucocorticoids and continued on a tapering course
226 for between six and twelve months. Case reports have described minimal response
227 from antacids or ranitidine [38-40].

228 **4.7. Crohn's Disease**

229 Discovery of Crohn's disease (CD) in the stomach or duodenum is relatively
230 frequent. A retrospective study of patients with known CD found histological

evidence of gastric disease in 41.5% of cases and duodenal lesions in 12% [41].
Nonetheless, upper gastrointestinal CD is usually subclinical and gastroduodenal involvement is the primary complaint in less than 1 in 20 patients with CD [42,43].
Even fewer patients will experience progression of their disease to peptic ulceration.

Treatment of upper tract CD is similar in principle to more distal disease. The medicinal regimen may comprise acid-suppression, glucocorticoids and immunomodulatory therapy if necessary. Sulfasalazine and mesalamine are ineffective options for this purpose because their principal site of action is the distal ileum and colon [44,45].

4.8. Stress Ulcer

Stress ulcers are the third commonest cause of PUD, accounting for 3-5% of cases overall [46]. Stress ulcers arise in patients with critical illness such as those hospitalised in the intensive care environment or in the post-operative state. They form principally due to splanchnic hypoperfusion. General practitioners are less likely than hospitalists to face this problem in routine practice but having an awareness of the condition remains important.

4.9. Idiopathic Ulcer

There remains a small group of patients with truly idiopathic ulcers. Idiopathic PUD is a diagnosis of exclusion. The pathogenesis of idiopathic PUD is uncertain but identified risk factors include smoking and psychological stress [47]. There is no definite management strategy however patients usually require long-term treatment with acid suppression agents to achieve and maintain symptom control.

254 5. RISK FACTORS FOR PEPTIC ULCERATION

255 Several medical comorbidities or environmental risk factors increase susceptibility to
 256 peptic ulceration without being capable of producing ulcer disease alone (Table 1).
 257 The mechanisms responsible for ulcer diathesis in these cases are not well known.
 258 Importantly, although these risk factors are not causative they do increase the
 259 likelihood of developing PUD and increase the likelihood of disease complications by
 260 impairing ulcer healing. A number of risk factors, such as alcohol or smoking, are
 261 widely believed to independently cause PUD although evidence in the literature to
 262 substantiate this belief is absent.

Table 1: Non-Causal Risk Factors for Peptic Ulceration

- Smoking
- Alcohol
- Psychological stress
- Organ transplantation
- Diabetes mellitus
- Cirrhosis
- Chronic kidney disease

263

264 6. CONCLUSION

265 Peptic ulcers are common and are typically attributable to *H.pylori* infection or NSAID
 266 use. While these aetiologies remain the most frequent causes of PUD their relative
 267 incidence compared with other less common pathologies is declining. This is

268 explained in part by the falling incidence of *H.pylori* infection and the availability of
269 NSAIDs with lower gastroduodenal toxicity.

270 Causes of non-*H.pylori* non-NSAID peptic ulceration are unfamiliar to many
271 clinicians. Primary care physicians should be aware of how to approach patients with
272 ulcer disease that is negative for *H.pylori* or unassociated with NSAIDs. In most
273 instances repeat evaluation for undetected NSAID use or *H.pylori* will identify one of
274 these two causes as the underlying reason for peptic ulceration. Occasionally,
275 however, further testing is required for more obscure causes of PUD which account
276 for approximately 10% of cases overall. Possessing at least some knowledge of the
277 various conditions implicated in the pathogenesis of PUD will enable improved
278 patient care when traditional causes and remedies are absent.

279 REFERENCES

- 280 1. Malfertheiner P, Chan F, McColl K. Peptic ulcer disease. Lancet 2009; 374:
281 1449-61.
- 282 2. Kumar V, Abbas A, Fausto N. Robbin's Basic Pathology. Philadelphia:
283 Elsevier Saunders; 2007.
- 284 3. Chan F, Leung W. Peptic ulcer disease. Lancet 2002; 360: 933-41.
- 285 4. Sung J, Kuipers E, El-Serag H. Systematic review: the global incidence and
286 prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29: 938-46.
- 287 5. Borody T, George L, Brandl S, Andrews P, Ostapowicz, Hyland L, et al.
288 *Helicobacter pylori* negative duodenal ulcer. Am J Gastroenterol 1991; 86(9):
289 1154.

- 290 6. Cai S, Rodriguez L, Masso-Gonzalez E, Hernandez-Diaz S. Uncomplicated
291 peptic ulcer in the UK: trends from 1997 to 2005. *Aliment Pharmacol Ther*
292 2009; 30: 1039-48.
- 293 7. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer
294 disease. *Aliment Pharmacol Ther* 1995; 9: 3-12.
- 295 8. Scheiman J, Herlitz J, Veldhuyzen van Zenten S, Lanas A, Agewell S,
296 Naucler E, et al. Esomeprazole for prevention and resolution of upper
297 gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid
298 for cardiovascular protection: the OBERON trial. *J Cardiovasc Pharmacol*
299 2013; 61(3) 250-57.
- 300 9. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al.
301 Relationship of *Helicobacter pylori* to serum pepsinogens in an asymptomatic
302 Japanese population. *Gastroenterology* 1992; 102(3):760.
- 303 10. Perez-Aisa M, Del Pino D, Siles M, Lanas A. Clinical trends in ulcer diagnosis
304 in a population with high prevalence of *Helicobacter pylori* infection. *Aliment*
305 *Pharmacol Ther* 2005; 21: 65-72.
- 306 11. Nishikawa K, Sugiyama T, Kato M, Ishizuka J, Komatsu Y, Kagaya H, et al.
307 Non-*Helicobacter pylori* and non-NSAID peptic ulcer disease in the
308 Japanese population. *Eur J Gastroenterol Hepatol* 2000; 12: 635-40.
- 309 12. Musumba C, Jorgensen A, Sutton L, Van Eker D, Moorcroft J, Hopkins M, et
310 al. The relative contribution of NSAIDs and *Helicobacter pylori* to the aetiology
311 of endoscopically-diagnosed peptic ulcer disease; observations from a tertiary
312 referral hospital in the UK between 2005 and 2010. *Aliment Pharmacol Ther*
313 2012; 36: 48-56.

- 314 13. Longmore M, Wilkinson I, Baldwin A, Wallin E. Oxford Handbook of Clinical
315 Medicine. Oxford: Oxford University Press; 2014.
- 316 14. Gisbert J, Calvert X. Review article: Helicobacter pylori negative duodenal
317 ulcer disease. Aliment Pharmacol Ther 2009; 30: 791-815.
- 318 15. McColl K. Helicobacter pylori negative ulcer disease. Digest Liver Dis 2000;
319 32: 125-27.
- 320 16. Wong G, Wong V, Chan Y, Ching J, Au K, Hui A, et al. High incidence of
321 mortality and recurrent bleeding in patients with Helicobacter pylori-negative
322 idiopathic bleeding ulcers. Gastroenterology 2009;137(2):525.
- 323 17. Löhr J, Nelson J, Oldstone M. Is herpes simplex virus associated with peptic
324 ulcer disease? J Virol 1990; 64(5):2168.
- 325 18. Yokose N, Tanabe Y, An E, Osamura Y, Sugiura T, Hosone M, et al. Acute
326 gastric mucosal lesions associated with cytomegalovirus infection in a non-
327 immunocompromised host. Intern Med 1995; 34(9): 883.
- 328 19. Gonzalez-Perez A, Garcia Rodriguez L. Upper gastrointestinal complications
329 among users of paracetamol. Basic Clin Pharmacol Toxicol 2006; 98: 297-
330 303.
- 331 20. Doherty M, Hawkey C, Goulder M, Gibb I, Hill N, Aspley S, et al. A
332 randomised controlled trial of ibuprofen, paracetamol or a combination tablet
333 of ibuprofen/paracetamol in community-derived people with knee pain. Ann
334 Rheum Dis 2011; 70: 1534-41.
- 335 21. BMJ, doi:10.1136/bmj.38883.479549.2F (published 13 July 2006).
- 336 22. Gulmez S, Lassen A, Aalykke C, Dall M, Andries A, Anderson B, et al.
337 Spironolactone use and the risk of upper gastrointestinal bleeding: a

- 338 population-based case-control study. *Br J Clin Pharmacol* 2008; 66(2): 294-
339 99.
- 340 23. Wilkins T, Khan N, Nabh A, Schade R. Diagnosis and management of upper
341 gastrointestinal bleeding. *Am Fam Physician* 2012; 85(5): 469-76.
- 342 24. Loke Y, Trivedi A, Singh S. Meta-analysis: gastrointestinal bleeding due to
343 interaction between selective serotonin reuptake inhibitors and non-steroidal
344 anti-inflammatory drugs. *Aliment Pharmacol Ther* 2007; 27: 31-40.
- 345 25. Graham D, Malaty H. Alendronate gastric ulcers. *Aliment Pharmacol Ther*
346 1999; 13: 515-19.
- 347 26. Lanza F, Hunt R, Thomson A, Provenza M, Blank M. Endoscopic comparison
348 of oesophageal and gastroduodenal effects of risedronate and alendronate in
349 postmenopausal women. *Gastroenterology* 2000; 119: 631-38.
- 350 27. Herrera A, Sarabia M, Gonzalez M. Effects of treatment with bisphosphates
351 on gastrointestinal and oesophageal mucosa in patients with osteoporosis:
352 pamidronate versus alendronate. *Curr Ther Res* 1999; 60(6): 307-13.
- 353 28. Thomson A, Marshall J, Hunt R, Provenza J, Lanza F, Royer M, et al. 14 day
354 endoscopy study comparing risedronate and alendronate in postmenopausal
355 women stratified by *Helicobacter pylori* status. *J Rheumatol* 2002; 29(9):
356 1965-74.
- 357 29. Martinek J, Hlavova K, Zavada F, Seifert B, Rejchert S, Urban O, et al. A
358 surviving myth – corticosteroids are still considered ulcerogenic by a majority
359 of physicians. *Scand J Gastroenterol* 2010; 45: 1156-61.
- 360 30. Piper J, Ray W, Daugherty J, Griffin M. Corticosteroid use and peptic ulcer
361 disease: role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med* 1991;
362 114(9): 735.

- 363 31.Conn H, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of
364 adverse events during steroid therapy. *J Intern Med* 1994; 236(6): 619.
- 365 32.Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal
366 bleeding: a systematic review and meta-analysis. *BMJ Open* 2014;
367 4:e004587. doi:10.1136/bmjopen-2013-004587.
- 368 33.Isenberg J, Walsh J, Grossman M. Zollinger-Ellison syndrome.
369 *Gastroenterology* 1973; 65(1):140.
- 370 34.Koop H, Koop I, Klein M, Stumpf M, Massarrat S, Arnold R. Irradiation-
371 induced duodenal ulcer disease refractory to ranitidine: healing by
372 omeprazole. *J Clin Gastroenterol* 1989; 11(6): 631-34.
- 373 35.Konda A, Savin M, Cappell M, Dufy M. Radiation microsphere-induced GI
374 ulcers after selective internal radiation therapy for hepatic tumours: an
375 underrecognised clinical entity. *Gastrointestinal Endoscopy* 2009; 70(3): 561-
376 67.
- 377 36.Garg M, Strauchen J, Warner R, Divino C. Radioembolisation-induced
378 gastroduodenal ulcer. *Am Surg* 2012; 78(5): 621-23.
- 379 37.Afshar K, Boyd-King A, Sharma OP, Shigemitsu H. Gastric sarcoidosis and
380 review of the literature. *J Natl Med Assoc* 2010; 102(5): 419-22.
- 381 38.Fireman Z, Sternberg A, Yarchovsky Y, Abu-Much S, Coscas D, Topilsky M,
382 et al. Multiple antral ulcers in gastric sarcoid. *J Clin Gastroenterol* 1997; 24(2):
383 97.
- 384 39.Ebert E, Kierson M, Hagspiel K. Gastrointestinal and hepatic manifestations of
385 sarcoidosis. *Am J Gastroenterol* 2008;103(12): 3184.
- 386 40.Akinyemi E, Rohewal U, Tangorra M, Martin A, Abdullah M. Gastric
387 Sarcodosis. *J Natl Med Assoc* 2006; 98(6): 948-49.

41. Oberhuber G, Hirsch M, Stolte M. High incidence of upper gastrointestinal tract involvement in Crohn's disease. *Virchow's Arch* 1998; 432: 49-52.
42. Annunziata M, Caviglia R, Papparella L, Cicala M. Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic workup. *Dig Dis Sci* 2012; 57: 1618-23.
43. Kefalas C. Gastroduodenal Crohn's disease. *BUMC Proceedings* 2003; 16: 147-51.
44. Tremaine W. Gastroduodenal Crohn's disease: medical management. *Inflam Bowel Dis* 2003; 9(2): 127-28.
45. Mottett C, Juillerat P, Gonvers J, Michetti P, Burnand B, Vader J, et al. Treatment of gastroduodenal Crohn's disease. *Digestion* 2005; 71(1): 37-40.
46. Woodford C, Yao C. *Essential Med Notes* 2013. Toronto: Toronto Notes for Medical Students Inc; 2013.
47. Quan C, Talley N. Management of peptic ulcer disease not related to *Helicobacter pylori* or NSAIDs. *Am J Gastroenterol* 2002; 97(12): 2950-61.
48. Peptic ulcer disease [internet]. 2015 [cited 2015 Mar 8]. Available from: <http://patients.gi.org/topics/peptic-ulcer-disease/>
49. Konturek P, Celinski K, Slomka M, Cichoz H, Burnat G, Naegal A, et al. Melatonin and its precursors L-tryptophan prevent acute gastric mucosal damage induced by aspirin in humans. *J Physiol Pharmacol* 2008; 59(2): 67-75.